860549P

C24:1 Glucosyl(β) Ceramide (d18:1/24:1(15Z))

Avanti Research^™ - A Croda Brand 860549P, powder

• Synonyme(s) : D-glucosyl-β-1,1′-N-nervonoyl-D-erythro-sphingosine
• Formule empirique (notation de Hill): C₄₈H₉₁NO₈
• Numéro CAS: 887907-50-8
• Poids moléculaire : 810.24
• Code UNSPSC : 12352211
• Nomenclature NACRES : NA.25

Propriétés

• Forme: powder
• Conditionnement: pkg of 1 × 5 mg (860549P-5mg)
• Fabricant/nom de marque: Avanti Research^™ - A Croda Brand 860549P
• Type de lipide: sphingolipids
• Conditions d'expédition: dry ice
• Température de stockage: −20°C
• Chaîne SMILES: [H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@@]([H])(NC(CCCCCCCCCCCCC/C=C\CCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O

Description

Description générale

β-Glucosylceramides or glucocerebrosides (GlcCers) are synthesized from the glycosphingolipids by β-GlcCer synthase. They are synthesized in Golgi and endoplasmic reticulum and localized in the cytosolic side of cell membrane. GlcCers are omnipresent.

Application

C24:1 Glucosyl(β) Ceramide (d18:1/24:1(15Z)) may be used:

• as a standard hexosylceramide for hydrophilic interaction chromatography-based liquid chromatography mass spectroscopy
• to test its nuclear factor of activated T-cells (NFAT) activation
• in human natural killer T (NKT) cell potency assays

Actions biochimiques/physiologiques

β-Glucosylceramides (β-GlcCer) levels are elevated inlevels in Gaucher′s disease, due to the deficiency of β-glucosidase. β-GlcCer participates in the inflammatory and acquired immune responses by binding mincle on myeloid cells and has immunostimulatory activity.

Conditionnement

5 mL Amber Glass Screw Cap Vial (860549P-5mg)

Informations légales

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids